Study the Relationship Between Obesity and Hepatitis C Replication
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2008 |
| End Date: | April 2011 |
To Assess the Antiviral Activity of Pioglitazone and Prednisone in Obese Subjects With HCV Genotype 1 or 4 Infection, Insulin Resistance and Liver Inflammation Related to Non-alcoholic Fatty Liver.
Patients with chronic hepatitis C viral infection (HCV) and with a BMI greater than 30Kg/m2
are refractory to medical treatment. Also, HCV replication seems to be affected when
modeling insulin resistance in replicon cell culture systems.
PPARg -agonist (Pioglitazone) is effective in controlling liver inflammation in obese
subjects with non-alcoholic steatohepatitis (NASH) and also improving insulin sensitivity.
Therefore, we hypothesize that improving insulin resistance and /or inflammation may affect
HCV replication and viral kinetics. Independently of PPARg pathways, blocking inflammation
may also alter HCV viral kinetics. Thus, Prednisone should serve as a control for
anti-inflammatory, PPARg- independent pathways.
We found this trial at
1
site
Click here to add this to my saved trials
